关注
Mark Moehle
标题
引用次数
引用次数
年份
LRRK2 inhibition attenuates microglial inflammatory responses
MS Moehle, PJ Webber, T Tse, N Sukar, DG Standaert, TM DeSilva, ...
Journal of Neuroscience 32 (5), 1602-1611, 2012
4912012
Abrogation of α-synuclein–mediated dopaminergic neurodegeneration in LRRK2-deficient rats
JPL Daher, LA Volpicelli-Daley, JP Blackburn, MS Moehle, AB West
Proceedings of the National Academy of Sciences 111 (25), 9289-9294, 2014
2372014
M1 and M2 immune activation in Parkinson’s disease: foe and ally?
MS Moehle, AB West
Neuroscience 302, 59-73, 2015
2282015
Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration
JPL Daher, HA Abdelmotilib, X Hu, LA Volpicelli-Daley, MS Moehle, ...
Journal of Biological Chemistry 290 (32), 19433-19444, 2015
2152015
LRRK2 secretion in exosomes is regulated by 14-3-3
KB Fraser, MS Moehle, JPL Daher, PJ Webber, JY Williams, CA Stewart, ...
Human molecular genetics 22 (24), 4988-5000, 2013
1802013
α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration
H Abdelmotilib, T Maltbie, V Delic, Z Liu, X Hu, KB Fraser, MS Moehle, ...
Neurobiology of disease 105, 84-98, 2017
1762017
Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers
KB Fraser, MS Moehle, RN Alcalay, AB West, LRRK2 Cohort Consortium, ...
Neurology 86 (11), 994-999, 2016
1342016
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents
AB West, RM Cowell, JPL Daher, MS Moehle, KM Hinkle, HL Melrose, ...
Journal of Comparative Neurology 522 (11), 2465-2480, 2014
1342014
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
NI Bohnen, AJ Yarnall, RS Weil, E Moro, MS Moehle, P Borghammer, ...
The Lancet Neurology 21 (4), 381-392, 2022
1082022
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins
MS Moehle, JPL Daher, TD Hull, R Boddu, HA Abdelmotilib, J Mobley, ...
Human molecular genetics 24 (15), 4250-4267, 2015
802015
Cholinergic projections to the substantia nigra pars reticulata inhibit dopamine modulation of basal ganglia through the M4 muscarinic receptor
MS Moehle, T Pancani, N Byun, SE Yohn, GH Wilson, JW Dickerson, ...
Neuron 96 (6), 1358-1372. e4, 2017
592017
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice
T Pancani, DJ Foster, MS Moehle, TJ Bichell, E Bradley, TM Bridges, ...
Proceedings of the National Academy of Sciences 112 (45), 14078-14083, 2015
482015
Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders
MS Moehle, PJ Conn
Movement Disorders 34 (8), 1089-1099, 2019
462019
Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury
R Boddu, TD Hull, S Bolisetty, X Hu, MS Moehle, JPL Daher, AI Kamal, ...
Human molecular genetics 24 (14), 4078-4093, 2015
452015
Unique functional and structural properties of the LRRK2 protein ATP-binding pocket
Z Liu, RA Galemmo, KB Fraser, MS Moehle, S Sen, LA Volpicelli-Daley, ...
Journal of Biological Chemistry 289 (47), 32937-32951, 2014
412014
Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators
SE Yohn, DJ Foster, DP Covey, MS Moehle, J Galbraith, ...
Molecular psychiatry 25 (11), 2786-2799, 2020
352020
Regional differences in expression of β-tubulin isoforms in schizophrenia
MS Moehle, RF Luduena, V Haroutunian, JH Meador-Woodruff, ...
Schizophrenia research 135 (1-3), 181-186, 2012
332012
Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy
MS Moehle, AM Bender, JW Dickerson, DJ Foster, A Qi, HP Cho, ...
ACS Pharmacology & Translational Science 4 (4), 1306-1321, 2021
192021
Co-activation of metabotropic glutamate receptor 3 and beta-adrenergic receptors modulates cyclic-AMP and long-term potentiation, and disrupts memory reconsolidation
AG Walker, DJ Sheffler, AS Lewis, JW Dickerson, DJ Foster, RK Senter, ...
Neuropsychopharmacology 42 (13), 2553-2566, 2017
172017
The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders
NE Chambers, M Millett Jr, MS Moehle
Biochemical Society Transactions 51 (2), 691-702, 2023
52023
系统目前无法执行此操作,请稍后再试。
文章 1–20